Are we using the optimal strategy for GBS management in pregnancy?
Yudin
Mark H
MH
Department of Obstetrics and Gynaecology, St. Michael's Hospital, University of Toronto, Toronto ON.
Shah
Vibhuti
V
Department of Paediatrics, Mount Sinai Hospital, University of Toronto, Toronto ON.
Ohlsson
Arne
A
Department of Paediatrics, Mount Sinai Hospital, University of Toronto, Toronto ON; Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto ON.
Farine
Dan
D
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto ON.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D005260:Female; D006801:Humans; D007226:Infant Mortality; D007231:Infant, Newborn; D008403:Mass Screening; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D013290:Streptococcal Infections / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control*; D013292:Streptococcus agalactiae / Q000187:drug effects; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents